multiple%20myeloma
MULTIPLE MYELOMA

Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion.

It accounts for 1-2% of all cancers worldwide & mostly affects patients at ages 65-74 years old.

Patient usually presents with bone pain & nonspecific symptoms, or due to abnormalities in laboratory exams.

 

Definition

  • A bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion

Signs and Symptoms

  • Patients usually present w/ bone pain & fatigue due to anemia
  • Nonspecific symptoms eg nausea, vomiting, malaise, weight loss, generalized body weakness, fatigue

Etiology

  • There are 2 processes being considered to be the root cause of multiple myeloma

Premalignant Stage: Appearance of MGUS

  • Brought about by the cytogenic abnormalities &/or abnormal cellular response to an antigenic stimulus
  • Malignant transformation of plasma cells leads to production of monoclonal paraprotein (M-protein) composed of single heavy & light chain immunoglobulins
    • Abnormal immunoglobulins include IgG, IgM, IgA, & rarely IgE & IgD
    • Light chain protein κ & λ are also seen
    • These immunoglobulins cause hyperviscosity & end-organ damage
  • Chromosomal aberrations identified w/ multiple myeloma include del17p13, IgH gene rearrangement at 14q32, 14q32 translocations [t(11;14)(q13;q32), t(4;14)(p16;q32), t(14;16)(q32;q23), t(14;20)(q32;q12)], & chromosome 1 abnormalities
    • These aberrations lead to the development of plasma cell clones 
  • An antigenic stimulus when interpreted by cells [eg toll-like receptors (TLRs) on myeloma cells, interleukin-6 (IL-6)] abnormally causes an increase in plasma cells, thereby causing chromosomal changes leading to plasma cell clones & abnormally produced immunoglobulins

Disease Progression from MGUS to Multiple Myeloma

  • Triggering factors that contribute to the development of MGUS into multiple myeloma include secondary cytogenic aberrations (secondary IgH translocation, Ras mutations, activation of the NF κ B pathway), abnormalities in the cell cycle pathway, interrupted apoptosis, & various factors affecting the bone marrow

Risk Factors

  • Age (increases risk)
  • Immunosuppression
  • Environmental exposures
  • Gender (more common in men)
  • Occupational exposure to toxic substances such as radiation, solvents, herbicides, insecticides

Epidemiology

  • Accounts for 1-2% of all cancers worldwide
    • 2nd most frequent hematologic malignancy in the US, w/ rapidly increasing incidence rate in Asia
  • Median age of onset is 66 years old

Pathophysiology

  • Always preceded by a premalignant stage, monoclonal gammopathy of undetermined significance (MGUS)
    • Only 10% of patients w/ newly diagnosed multiple myeloma have a history of pre-existing MGUS since patients w/ MGUS are asymptomatic
    • Rate of progression of MGUS to multiple myeloma is 1% per year
    • Non-IgM immunoglobulin MGUS (non-IgM MGUS) makes up 80% of premalignant multiple myeloma
    • Light-chain immunoglobulin MGUS makes up 20% of premalignant multiple myeloma
    • IgM immunoglobulin MGUS usually develops into Waldenström macroglobulinemia but may rarely evolve into multiple myeloma (IgM myeloma)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 28 Jun 2019
Adjuvant treatment with ipilimumab significantly improved overall survival (OS) among patients with resected high-risk melanoma compared with high-dose interferon-α2b (HDI*), according to final results of the North American Intergroup E1609** trial presented at ASCO 2019.
Elaine Soliven, 18 Jun 2019
Neoadjuvant treatment with trastuzumab emtansine (T-DM1) plus pertuzumab led to an elevated risk of 3-year event-free survival (EFS) events in patients with HER2-positive breast cancer, according to a secondary analysis of the KRISTINE* trial presented at ASCO 2019.
Audrey Abella, 14 Jun 2019
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.
Audrey Abella, 11 Jul 2019
Augmenting the triple chemotherapeutic regimen FOLFOXIRI* with bevacizumab demonstrated favourable efficacy regardless of age and gender in patients with unresectable metastatic colorectal cancer (mCRC), according to data presented at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) 2019.